$CNSY

CERENOME, INC.

Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. Its wholly owned subsidiary, CNSide Diagnostics, develops and commercializes laboratory-developed tests, including the CNSide Test, which detects and characterizes tumor cells in cerebrospinal fluid. The company also develops rhenium (186Re) obisbemeda, an investigational radiotherapy for central nervous system cancers, and 188RNL-BAM, a preclinical radiotherapeutic device intended for solid organ cancers, initially liver cancer. Plus Therapeutics makes money through its diagnostic testing business and intends to commercialize its therapeutic products if developed and approved. The CNSide Test is provided through a centralized laboratory in Houston, where the company is headquartered. Plus Therapeutics also works with third parties to develop, manufacture and supply its radiotherapeutic product candidate.

7
0
2

No SEC Form 4 filings for $CNSY in the last 30 days.

See all $CNSY insider activity →

Cerenome Reports Interim REYOBIQ Data: No Dose-Limiting Toxicities in First 10 Patients

Cerenome reported interim data from the ReSPECT-LM study, showing no dose-limiting toxicities in the first 10 patients treated with REYOBIQ. One patient received three doses totaling 79.2 mCi, with consistent radiation delivery. No leptomeningeal (LM) progression was observed at three or six months, with one case at nine months. Cerenome plans a Phase 2 study in 2027, pending regulatory alignment.

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early di

CNSY sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 9 news stories mentioning CNSY (CERENOME, INC.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 2 bearish.

Recent CNSY coverage spans financial news, earnings and technology.

What's driving CNSY

AlphAI scores every news story that mentions CNSY with an AI model for sentiment and relevance, and aggregates insider trades from CERENOME, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNSY

Score

Cerenome Reports Interim REYOBIQ Data: No Dose-Limiting Toxicities in First 10 Patients

Cerenome reported interim data from the ReSPECT-LM study, showing no dose-limiting toxicities in the first 10 patients treated with REYOBIQ. One patient received three doses totaling 79.2 mCi, with consistent radiation delivery. No leptomeningeal (LM) progression was observed at three or six months, with one case at nine months. Cerenome plans a Phase 2 study in 2027, pending regulatory alignment.

$CNSYMedAI 8/10Clinical / regulatory

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early di

$CNSYMedAI 8/10Earnings

Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement…

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress HOUSTON, November 13, 2026 – Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology

$CNSYLowExec change· appointed

CERENOME, INC. (CNSY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Cerenome Appoints Director Ron Andrews as Chief Business Officer Executive board member with 35-plus years of diagnostics leadership and more than $15 billion in strategic exits to drive CNSide ® growth and strategic partnerships HOUSTON, November 10, 2026 (GLOBE NEW

Related tickers